vimarsana.com

Latest Breaking News On - Summit therapeutics inc stock exchange - Page 1 : vimarsana.com

Purcell & Lefkowitz LLP Is Investigating Summit Therapeutics Inc for Potential Breaches of Fiduciary Duty By Its Board of Directors

NEW YORK, June 5, 2023 /PRNewswire/ Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty. | June 5, 2023

Roberth lefkowitzPurcell lefkowitzSummit therapeutics incPrnewswire purcell lefkowitzSummit therapeuticsSummit therapeutics inc stock exchangePress releaseIduciary smmt us86627t1088

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

Data Supporting Summit’s Planned Phase III Trial for First-line Metastatic Squamous NSCLC Patients on Display Phase II ORR of 67% with a mDOR of 15 months in 1L SQ-NSCLC Patients . | June 4, 2023

Li zhangYu zhangUnited statesUnited kingdomLi zhuangMing zhouWu zhuangMenlo parkYuanyuan zhaoMichelle xiaLikun chenYanqiu zhaoQitao yuJianhua chenBryan huangYunpeng yang

Ivonescimab Updated Data to be Featured at ASCO 2023

Summit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab . | June 1, 2023

Li zhangUnited kingdomYu zhangMenlo parkUnited statesMing zhouLi zhuangWu zhuangWeidong zhangBryan huangJianhua chenQitao yuYanqiu zhaoMichelle xiaYuanyuan zhaoNingning zhou

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2023

First US Patient Treated in Ivonescimab Clinical Trial after Closing Agreement; $500M Raised in Fully-Subscribed Rights Offering . | May 11, 2023

United kingdomUnited statesMenlo parkMaky zanganehRobertw dugganYu michelle xiaCrown bioscienceBiopharma incCompany board of directorsCelera genomics incTeam summitSummit therapeutic mission statementSummit therapeutics incBayer corporationAbbvie incCompany co

Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)

Phase III Study Designed to Establish the Effect of Ivonescimab in Lung Cancer Patients Whose Tumors Progressed after EGFR-TKI Therapy . | May 9, 2023

Menlo parkUnited statesUnited kingdomMaky zanganehIan andersonRobertw dugganOncologist at providence medical foundationAmerican cancer societyTeam summitWorld health organizationAkeso incSummit therapeutic mission statementSummit therapeutics incSummit therapeuticsUnited states basedMedical oncologist

vimarsana © 2020. All Rights Reserved.